Glaxo employs about 97,000 people in more than 100 countries, and about 1,300 work in Center City. Others work locally in Upper Merion, Upper Providence, and Conshohocken; other facilities are in Pittsburgh; Marietta, Pa.; and Clifton and Parsippany, N.J.
Workers in Center City, who are now at Logan Square, are scheduled to begin moving to a new building at the Navy Yard in January.
Witty said his company, like many, made contingency plans for operating during the storm and its aftermath, including producing drugs to mitigate shortages that they could control.
"We stand ready, for any state or city that needs help. We are a phone call away," Witty said. "You can't be anything but shocked looking at the pictures."
Witty, who recently took the Glaxo board of directors to India for a meeting, spoke to reporters and financial analysts from Singapore, and he used the location to emphasize that the quarter's highlights came from emerging markets.
Glaxo's division that deals with emerging markets and the Asia-Pacific region had 11 percent revenue growth for the quarter, he said, with China and India leading that group.
"Forty-one percent of our revenue comes from outside America and Europe," Witty said.
Overall, Glaxo reported that its sales revenue in the three months ending Sept. 30 declined to $10.5 billion from $11.5 billion in the same period in 2011. Profit for that period declined from $2.3 billion to $1.9 billion.
Witty attributed reduced third-quarter revenue and profits to several factors, but he focused on pricing pressure from European governments cutting reimbursement payments for medicine.
He said that it was understandable that Greece, given its well-publicized financial problems, would cut reimbursements, but that better-off countries such as Germany were following suit.
"There is not very much cause for optimism," Witty said of the European pricing problem.
Contact David Sell at dsell@ phillynews.com or 215-854-4506. Read his blog at www.philly.com/phillypharma and on Twitter @phillypharma.